Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution

被引:111
作者
Aliabadi, HM [1 ]
Brocks, DR [1 ]
Lavasanifar, A [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
基金
加拿大健康研究院;
关键词
cyclosporine A; block copolymer micelles; biodistribution; drug delivery; polyethylene oxide; polycaprolactone;
D O I
10.1016/j.biomaterials.2005.05.042
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The aim of this study was to assess the potential of polymeric micelles to modify the pharmacokinetics and tissue distribution of cyclosporine A (CsA). Drug-loaded methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) (PEO-b-PCL) micellar solutions in isotonic medium were prepared and administered intravenously to healthy Sprague-Dawley rats. Blood and tissues were harvested and assayed for CsA, and resultant pharmacokinetic parameters and tissue distribution of CsA in its polymeric micellar formulation were compared to its commercially available intravenous formulation (Sandimmune (R)). In the pharmacokinetic assessment, a 6.1 fold increase in the area under the blood concentration versus time curve (AUC) was observed for CsA when given as polymeric micellar formulation as compared to Sandimmune (R). The volume of distribution and clearance of CsA as PEO-b-PCL formulation were observed to be 10.0 and 7.6 fold lower, respectively, compared to the commercial formulation. No significant differences in t(1/2) or MRT could be detected. In the biodistribution study, analysis of tissue samples indicated that the mean AUC of CsA in polymeric micelles was lower in liver, spleen and kidney (1.5, 2.1 and 1.4-fold, respectively). Similar to the pharmacokinetic study in these rats, the polymeric micellar formulation gave rise to 5.7 and 4.9-fold increase in the AUC of CsA in blood and plasma, respectively. Our results show that PEO-b-PCL micelles can effectively solubilize CsA, at the same time confining CsA to the blood circulation and restricting its access to tissues such as kidney, perhaps limiting the onset of toxicity. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7251 / 7259
页数:9
相关论文
共 28 条
[1]   Micelles of methoxy poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization and controlled delivery of Cyclosporine A [J].
Aliabadi, HM ;
Mahmud, A ;
Sharifabadi, AD ;
Lavasanifar, A .
JOURNAL OF CONTROLLED RELEASE, 2005, 104 (02) :301-311
[2]   Chronic cyclosporine nephrotoxicity [J].
Andoh, TF ;
Bennett, WM .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (03) :265-270
[3]   TESTING FOR THE EQUALITY OF AREA UNDER THE CURVES WHEN USING DESTRUCTIVE MEASUREMENT TECHNIQUES [J].
BAILER, AJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1988, 16 (03) :303-309
[4]   Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation [J].
Brocks, DR ;
Betageri, GV .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (08) :1049-1053
[5]   High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard [J].
Chimalakonda, AP ;
Shah, RB ;
Mehvar, R .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 772 (01) :107-114
[6]   LIPOSOMAL CYCLOSPORINE - COMPARISON OF DRUG LIPID CARRIER PHARMACOKINETICS AND BIODISTRIBUTION [J].
CHOICE, E ;
MASIN, D ;
BALLY, MB ;
MELOCHE, M ;
MADDEN, TD .
TRANSPLANTATION, 1995, 60 (09) :1006-1011
[7]  
CURTIS JJ, 1988, TRANSPLANT P, V20, P540
[8]   LIPOSOMAL FORMULATIONS OF CYCLOSPORINE-A - INFLUENCE OF LIPID TYPE AND DOSE ON PHARMACOKINETICS [J].
FAHR, A ;
HOLZ, M ;
FRICKER, G .
PHARMACEUTICAL RESEARCH, 1995, 12 (08) :1189-1198
[9]   CYCLOSPORINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN IMMUNOREGULATORY DISORDERS [J].
FAULDS, D ;
GOA, KL ;
BENFIELD, P .
DRUGS, 1993, 45 (06) :953-1040
[10]   Block copolymer micelles for drug delivery: design, characterization and biological significance [J].
Kataoka, K ;
Harada, A ;
Nagasaki, Y .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) :113-131